title: Antitumor activity of recombinant human interleukin-1 against heterotransplanted human non-Hodgkin lymphomas in nude mice.
abstract: Antitumor activity of recombinant human interleukin 1 alpha (IL-1) against seven human non-Hodgkin lymphomas grown in athymic nude mice was studied. Growth of the lymphomas was markedly inhibited after an injection of 0.4 mg/kg IL-1. The growth inhibition of Burkitt lymphoma was found to be dose-dependent up to 0.4 mg/kg, reaching a plateau thereafter. The loss of colony-forming ability of the cells and the loss of cell viability showed the same type of dose-dependence and progressed during 24 h following an injection of IL-1. In accordance with these observations, histopathologic examination revealed progressively spreading coagulative necrosis without bleeding. Little infiltration of inflammatory cells into the tumor tissue was observed. IL-1 growth inhibition of T lymphoma in beige nude mice having low natural killer activity was similar to that in nude mice. These findings suggested that the antitumor effects might not be produced through cell-mediated antitumor actions. Immunocytological examination with anti-IL-1 antibody revealed that administered IL-1 was bound to the lymphoma cells, suggesting that IL-1 receptor is probably expressed on these cells in vivo. The antitumor action of IL-1 on the lymphomas may be exerted directly through the IL-1 receptor.
authors: Hospital National Institute of Radiological Sciences, Chiba.
authors: T
authors: T
authors: Miyamoto
authors: S G
authors: SG
authors: Wu
mesh_terms: D000818:Animals; D002051:Burkitt Lymphoma / Q000188:drug therapy; D002455:Cell Division / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006825:Hybridomas; D007375:Interleukin-1 / Q000627:therapeutic use*; D007399:Interphase; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy* / Q000473:pathology; D016399:Lymphoma, T-Cell / Q000188:drug therapy; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011994:Recombinant Proteins / Q000627:therapeutic use; D013997:Time Factors
chemical_list: D007375:Interleukin-1; D011994:Recombinant Proteins